STOCK TITAN

Ceribell (CBLL) SEC Filings, Aug 10-19, 2026

CBLL NASDAQ

CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.

The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.

Rhea-AI Summary

Ceribell, Inc. (CBLL) officer Scott E. Blumberg reported a proposed sale of 33,512 common shares, with an aggregate market value of $838,820.29 and an approximate sale date of August 19, 2026. The shares were acquired from the issuer through a cash-paid stock option exercise on August 19, 2026.

The notice lists December 12, 2025 as the date of plan adoption or instruction under Rule 10b5-1. It also reports prior sales by Blumberg of 1,387 shares for gross proceeds of $24,960.31 on May 21, 2026, and 990 shares for $24,750.00 on August 18, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
other
-
Rhea-AI Summary

Ceribell, Inc. (CBLL) is the issuer for a planned resale of its common stock under Rule 144 by security holder Xingjuan Chao, using Fidelity Brokerage Services LLC as broker. The notice covers a proposed sale of 31,415 shares of common stock, with an aggregate market value of $786,364.46, when 38,378,101 shares of this class were outstanding as of 08/19/2026.

The shares to be sold were acquired through a stock option exercise on 04/30/2018, for cash, from the issuer. The filing also lists several prior sales of Ceribell common stock by Xingjuan Chao during the past three months, reflecting ongoing liquidity activity by this holder.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
other
-
Rhea-AI Summary

Ceribell, Inc. officer and director Xingjuan Chao reported a proposed sale of 2,199 common shares, with an aggregate market value of $54,975.00 and an approximate sale date of August 18, 2026. The shares were acquired from the issuer through a stock option exercise paid in cash on August 18, 2026. The reported date for plan adoption or giving of instruction under Rule 10b5-1 is September 12, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.81%
Tags
other
Rhea-AI Summary

Ceribell, Inc. (CBLL) is the issuer of common stock that an affiliate, Scott E. Blumberg, has notified for potential sale under Rule 144. The notice covers 990 shares of common stock to be sold through Fidelity Brokerage Services LLC on or after 08/18/2026, with an indicated value of $24,750.00. The shares are to be acquired via a stock option exercise from the issuer for cash. In the prior three months, Blumberg previously sold 1,387 shares of Ceribell common stock on 05/21/2026 for proceeds of $24,960.31.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.81%
Tags
other
-
Rhea-AI Summary

Ceribell, Inc. executive Xingjuan Chao, President and CEO, reported option exercises on August 13, 2026. She exercised stock options for 8,096 shares of common stock at an exercise price of $2.24 per share and for 25,000 shares at $3.65 per share, converting derivative awards into common stock. A separate holding entry shows 369,088 shares of common stock held indirectly by the ACP 2021 Trust, where she is co-trustee and may be deemed to share beneficial ownership, while disclaiming beneficial ownership except to the extent of her pecuniary interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
insider
-
Rhea-AI Summary

Ceribell, Inc. received an amended Schedule 13G/A reporting that investment entities affiliated with TPG GP A, LLC, together with James G. Coulter and Jon Winkelried, collectively report beneficial ownership of 2,975,566 shares of Ceribell common stock. These shares are held directly by The Rise Fund Clearthought, L.P., over which TPG GP A exercises indirect control. Based on 38,378,101 shares of common stock outstanding as of August 6, 2026, the reported stake represents 7.8% of Ceribell’s common stock. The reporting persons share voting and dispositive power over these shares and disclaim beneficial ownership except to the extent of any pecuniary interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.59%
Tags
ownership
Rhea-AI Summary

Ceribell, Inc. director Joseph Michael Taylor reported a sale of common stock. On 2026-08-13, he sold 13,095 shares of Ceribell common stock in a sale categorized as an open market or private transaction at $23.40 per share. Following this transaction, he directly holds 48,478 shares of Ceribell common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
insider
-
Rhea-AI Summary

Ceribell, Inc. (CBLL) director Joseph Michael Taylor filed a notice listing 13,095 common shares to be sold, with an aggregate market value of $300,000.00 and an approximate sale date of August 13, 2026. The notice lists 38,380,000 shares outstanding. A prior-sales entry lists Joseph Taylor's sale of 5,500 common shares for gross proceeds of $101,255.00 on June 11, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
other
-
Rhea-AI Summary

Ceribell, Inc. reported strong top-line growth but continued losses for the quarter and six months ended June 30, 2026. Total revenue rose to $28.1 million for the quarter and $54.6 million year-to-date, up 33% and 31% from 2025, driven by higher sales of disposable EEG Wearables and subscription fees as adoption expanded to more than 700 hospitals.

Gross margin improved to 92% in the quarter and 90% year-to-date, helped by scale and a $1.6 million IEEPA tariff refund. Operating expenses grew 36% year-to-date to $89.8 million, mainly from increased headcount, commercialization, and IP-related legal costs, leading to a net loss of $19.3 million for the quarter and $39.0 million year-to-date. The company held $129.3 million in cash, cash equivalents, and marketable securities and believes this will fund operations for at least 12 months. Subsequent to quarter-end, Ceribell refinanced its term loan with a new credit facility that includes a $30 million term loan commitment and a revolving line initially sized at $20 million, of which $20 million was drawn to repay the prior facility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.41%
Tags
quarterly report
Rhea-AI Summary

Ceribell, Inc. reported strong top-line growth for the quarter ended June 30, 2026. Total revenue was $28.1 million, up 33% from $21.2 million a year earlier, driven by new account additions and higher utilization across its installed base. Product revenue reached $21.2 million and subscription revenue $6.9 million, both rising about 30% year over year. The company ended the quarter with 712 active accounts.

Profitability remains negative but margins are high. Gross profit was $25.9 million with a 92% gross margin, aided by manufacturing efficiencies, a new Vietnam line, and one-time tariff refunds. Operating expenses increased 37% to $45.9 million as Ceribell invested in commercial expansion, R&D, and legal costs. Net loss widened to $19.3 million, or $0.51 per share, while Adjusted EBITDA loss was $9.8 million.

The balance sheet showed $129.3 million in cash, cash equivalents, and marketable securities at June 30, 2026. Ceribell subsequently entered a new credit facility providing access to up to $60 million in committed capital. The company raised its 2026 revenue outlook to $114–$117 million, implying about 28–31% growth. It also highlighted multiple FDA 510(k) clearances and a CMS New Technology Add-On Payment for its delirium monitoring solution, effective October 1, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.41%
Tags
current report

FAQ

How many Ceribell (CBLL) SEC filings are available on StockTitan?

StockTitan tracks 185 SEC filings for Ceribell (CBLL), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Ceribell (CBLL)?

The most recent SEC filing for Ceribell (CBLL) was filed on November 17, 2026.